AI assistant
Edgewise Therapeutics, Inc. — Director's Dealing 2021
Mar 26, 2021
31829_dirs_2021-03-25_e5a9508d-933a-4e3c-b71b-f8dbb2e0bad2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-03-25
Reporting Person: Thompson Peter A. (Director, 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 316920 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Preferred Stock | $0.00 | Common Stock (8187100) | Indirect | ||
| Series B-1 Preferred Stock | $0.00 | Common Stock (1572960) | Indirect | ||
| Series B-2 Preferred Stock | $0.00 | Common Stock (1301626) | Indirect | ||
| Series C Preferred Stock | $0.00 | Common Stock (1668350) | Indirect | ||
| Series C Preferred Stock | $0.00 | Common Stock (272724) | Indirect |
Footnotes
F1: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.
F2: Immediately prior to the completion of the Issuer's initial public offering of Common Stock, each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock shall be exchanged at a 1:1 ratio for shares of Common Stock. The shares of Preferred Stock have no expiration date.
F3: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borbo and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis.